Overview

Single Dose Pharmacokinetic (PK) Study Of Paroxetine CR(12.5-37.5mg) In Healthy Chinese Subjects

Status:
Completed
Trial end date:
2006-04-26
Target enrollment:
Participant gender:
Summary
The study was designed to describe the relationship between dose and pharmacokinetic parameters of paroxetine over the range of proposed dosage strengths of the paroxetine CR tablet (12.5 to 37.5 mg) as well as safety profile
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Paroxetine